Detection of CBF beta/MYH11 fusion transcript: Value of minimal residual disease follow-up

被引：0
|
作者：
Costello, R
Cusenier, A
Sainty, D
Mozziconacci, MJ
Arnoulet, C
Blaise, D
Novakovitch, G
Maraninchi, D
Gastaut, JA
LafagePochitaloff, M
Gabert, J
机构：
[1] CTR CANC,DEPT BIOL,F-13009 MARSEILLE,FRANCE
[2] CTR CANC,DEPT CLIN HEMATOL,F-13009 MARSEILLE,FRANCE
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 1996年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：825 / 825
页数：1
相关论文
共 50 条
  • [41] Diagnosis and follow-up of minimal residual disease (MRD) in APL using FISH analysis
    Morschhauser, F
    Fournier, M
    Fenaux, P
    Chomienne, C
    Preudhomme, C
    BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (01) : 100 - 100
  • [42] Absence of minimal residual disease (MRD) by reverse transcription polymerase chain reaction (RT-PCR) in CBF beta/MYH11-associated acute myeloid leukemia.
    Marcucci, G
    Caligiuri, MA
    Oberkircher, AR
    Bloomfield, CD
    BLOOD, 1997, 90 (10) : 270 - 270
  • [43] Chronic myeloid leukemia with variant e19a2 BCR-ABL1 fusion transcript: interest of the molecular identification at diagnosis for minimal residual disease follow-up
    Gendron, Nicolas
    Belhouachi, Nabila
    Morel, Veronique
    Azgui, Zahia
    Maloum, Karim
    Florence Nguyen-Khac
    Cayuela, Jean-Michel
    Davi, Frederic
    Merle-Beral, Helene
    Chapiro, Elise
    ANNALES DE BIOLOGIE CLINIQUE, 2014, 72 (03) : 359 - 366
  • [44] Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB-MYH11 gene fusion
    van der Reijden, BA
    Simons, A
    Luiten, E
    van der Poel, SC
    Hogenbirk, PE
    Tönnissen, E
    Valk, PJM
    Löwenberg, B
    De Greef, GE
    Breuning, MH
    Jansen, JH
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 118 (02) : 411 - 418
  • [45] Therapy-related myelodysplastic syndrome with inv(16)(p13q22) and I type CBFβ/MYH11 after autologous transplantation:: Undetectable fusion transcript in pretransplant progenitor cells
    Yamamoto, K
    Nishikawa, S
    Minagawa, K
    Yakushijin, K
    Okamura, A
    Matsui, T
    LEUKEMIA RESEARCH, 2006, 30 (03) : 354 - 361
  • [46] Very long-term molecular follow-up of minimal residual disease in patients with neuroblastoma
    Tchirkov, Andrei
    Greze, Victoria
    Plantaz, Dominique
    Rouel, Nadege
    Vago, Philippe
    Kanold, Justyna
    PEDIATRIC BLOOD & CANCER, 2018, 65 (12)
  • [47] Minimal residual disease in mycosis fungoides follow-up can be assessed by polymerase chain reaction
    Poszepczynska-Guigne, E
    Bagot, M
    Wechsler, J
    Revuz, J
    Farcet, JP
    Delfau-Larue, MH
    BRITISH JOURNAL OF DERMATOLOGY, 2003, 148 (02) : 265 - 271
  • [48] Classifying AML Patients with Inv(16) into High-Risk and Low-Risk Released Patients Based on Peritransplantation Minimal Residual Disease Determined By CBF(I)over-cap2/MYH11 Gene Expression
    Zhao, Xiaosu
    Cao, Leqing
    Qin, Yazhen
    Zhang, Xiaohui
    Xu, Lanping
    Huang, Xiaojun
    Chang, Ying-Jun
    BLOOD, 2018, 132
  • [49] Usefulness of fish in the diagnosis and follow-up of minimal residual disease (MRD) in acute promyelocytic leukemia (APL).
    Morschhauser, F
    Fenaux, P
    Fournier, M
    Chomienne, C
    Preudhomme, C
    BLOOD, 1998, 92 (10) : 75A - 75A
  • [50] Follow-up of minimal residual disease in pediatric acute myeloblastic leukemia using metaphase-FISH
    Vettenranta, K
    Autio, K
    Hovi, L
    Knuutila, S
    Saarinen-Pihkala, UM
    LEUKEMIA & LYMPHOMA, 2002, 43 (06) : 1261 - 1265
12345